Austin Health at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Austin Health takes part in 4 sessions at CTAD 2026 in Boston. Its program spans tau PET diagnosis and the national rollout of anti-amyloid treatment in Australia. Its work covers a tau tracer's diagnostic performance, a real-world treatment registry and a community of practice for new therapies.

Organization	CTAD 2026 Attendance
Austin Health Melbourne, Australia
austin.org.au Hospitals & health systems Melbourne public hospital whose molecular imaging department runs amyloid and tau PET research, including for the AIBL study.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies (P077) PET and MRI imaging Poster Thu Nov 19 7:15am–5:00pm Associations of frailty, cognition and amyloid status in preclinical Alzheimer’s disease in prerandomization data from the AHEAD 3-45 study (P415) Prevention and early disease Poster Thu Nov 19 7:15am–5:00pm From readiness to real-world implementation: a national Community of Practice for novel Alzheimer’s disease therapies in Australia (P465) Real-world data and access · Anti-amyloid and anti-tau therapies Poster Thu Nov 19 7:15am–5:00pm National Real-World Use of Amyloid-Targeting Therapies in Australia: Early Experience from the ADNeT mAbs Registry (P466) Anti-amyloid and anti-tau therapies · Real-world data and access

Organization

CTAD 2026 Attendance

Austin Health

Melbourne, Australia

austin.org.au

Hospitals & health systems

Melbourne public hospital whose molecular imaging department runs amyloid and tau PET research, including for the AIBL study.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies (P077)

PET and MRI imaging

Poster

Thu Nov 19
7:15am–5:00pm

Associations of frailty, cognition and amyloid status in preclinical Alzheimer’s disease in prerandomization data from the AHEAD 3-45 study (P415)

Prevention and early disease

Poster

Thu Nov 19
7:15am–5:00pm

From readiness to real-world implementation: a national Community of Practice for novel Alzheimer’s disease therapies in Australia (P465)

Real-world data and access · Anti-amyloid and anti-tau therapies

Poster

Thu Nov 19
7:15am–5:00pm

National Real-World Use of Amyloid-Targeting Therapies in Australia: Early Experience from the ADNeT mAbs Registry (P466)

Anti-amyloid and anti-tau therapies · Real-world data and access

Instantly find 20 buyers from Austin Health

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction